Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAspirus Arise Abraxane Coverage Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentAspirus ArisePOLICY

    Oncology (Injectable) - Abraxane Utilization Review Medical Policy

    Customize your policy alerts

    Sign up for Aspirus Arise POLICY alerts

    Get alerted when POLICY changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare plan coverage and prior authorization criteria for Abraxane (paclitaxel albumin‑bound) for multiple cancer indications; applies to Aspirus Medicare Plans and providers seeking medical benefit coverage.

    Policy Summary
    PayerAspirus Arise
    PolicyOncology (Injectable) - Abraxane Utilization Review Medical Policy
    Policy CodePolicy POLICY
    Change TypeNo material changes
    Effective DateJan 1, 2022
    Last ReviewOct 22, 2025
    Next Review DateOct 22, 2025
    Key ActionObtain prior authorization and document indication, age ≥18, prior therapies when required, and biomarker status as specified.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12distinct cancer indications with approval criteria listed
    1 yearstandard authorization duration for approvals
    Dose rangesmultiple dosing regimens referenced
    Excludedconditions not recommended for approval

    Recommended Authorization Criteria

    Breast Cancer - Initial or recurrent/metastatic

    Approve for 1 year if ALL of the following are met

    Breast Cancer Approval: A) Patient is ≥ 18 years of age (IC-COMP) AND B) Patient meets ONE of the following: (i) The patient has recurrent or metastatic breast cancer and ONE of: (a) HER2-negative disease (IC-COMP) OR (b) triple-negative breast cancer (IC-COMP) OR (c) HER2-positive disease when paclitaxel albumin-bound will be used in combination with trastuzumab (IC-COMP); OR (ii) Patient has had a hypersensitivity reaction to paclitaxel or docetaxel (IC-COMP).

    Dosing: Approve ONE of: A) up to 260 mg/m2 IV once every 3 weeks; OR B) up to 125 mg/m2 IV three times per 28-day cycle.

    Non‑Small Cell Lung Cancer (NSCLC)

    Approve for 1 year if ALL of the following are met

    NSCLC Approval: A) Patient is ≥ 18 years of age (IC-COMP) AND B) Patient has recurrent, advanced, or metastatic non-small cell lung cancer (NSCLC) (IC-COMP) AND C) Patient meets ONE of the following: (i) BOTH: tumor is negative for actionable biomarkers (EGFR exon 19 deletion or exon 21 L858R, ALK, RET, ROS1) AND medication is used as initial or subsequent therapy (IC-COMP); OR (ii) BOTH: medication will be used as subsequent therapy AND tumor is positive for one of: EGFR exon 19 deletion or exon 21 L858R OR EGFR S768I/L861Q/G719X OR RET rearrangement OR ALK rearrangement OR ROS1 rearrangement (IC-COMP); OR (iii) Patient has had a hypersensitivity reaction to paclitaxel or docetaxel (IC-COMP).

    Dosing: Approve up to 100 mg/m2 IV no more frequently than three times in each 21-day cycle.

    Pancreatic Adenocarcinoma

    Approve for 1 year if ALL of the following are met

    Pancreatic Adenocarcinoma Approval: A) Patient is ≥ 18 years of age (IC-COMP) AND B) Medication will be used in combination with gemcitabine (IC-COMP).

    Dosing: Approve up to 125 mg/m2 IV no more frequently than three times in each 28-day cycle.

    Ampullary Adenocarcinoma

    Approve for 1 year if ALL of the following are met

    Ampullary Approval: A) Patient is ≥ 18 years of age (IC-COMP) AND B) Medication will be used in combination with gemcitabine (IC-COMP).

    Dosing: Approve up to 125 mg/m2 IV no more frequently than three times in each 28-day cycle.

    Melanoma (unresectable or metastatic)

    Approve for 1 year if ALL of the following are met

    Melanoma Approval: A) Patient is ≥ 18 years of age (IC-COMP) AND B) Patient has unresectable or metastatic melanoma (IC-COMP) AND C) At least one other systemic therapy for melanoma has been tried (examples listed in policy).

    Dosing: Approve up to 150 mg/m2 IV no more frequently than three times in each 28-day cycle.

    Cervical Cancer (subsequent therapy)

    Approve for 1 year if BOTH are met

    Cervical Cancer Approval: A) Patient is ≥ 18 years of age (IC-COMP) AND B) Medication will be used as subsequent therapy (IC-COMP).

    Dosing: Approve up to 125 mg/m2 IV no more frequently than three times in each 28-day cycle.

    Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Approve for 1 year if ALL of the following are met

    Ovarian/FT/Peritoneal Approval: A) Patient is ≥ 18 years of age (IC-COMP) AND B) Patient meets ONE of: (i) persistent or recurrent disease AND at least one other systemic chemotherapy regimen has been tried (IC-COMP) OR (ii) hypersensitivity to paclitaxel or docetaxel (IC-COMP).

    Dosing: Approve ONE of: A) up to 260 mg/m2 IV once every 3 weeks; OR B) up to 100 mg/m2 IV three times per 28-day cycle.

    Uveal Melanoma

    Approve for 1 year if BOTH are met

    Uveal Melanoma Approval: A) Patient is ≥ 18 years of age (IC-COMP) AND B) Patient has metastatic or unresectable disease (IC-COMP).

    Dosing: Approve up to 150 mg/m2 IV no more frequently than three times in each 28-day cycle.

    Endometrial Carcinoma

    Approve for 1 year if BOTH are met

    Endometrial Approval: A) Patient is ≥ 18 years of age (IC-COMP) AND B) Patient has recurrent or metastatic disease (IC-COMP).

    Dosing: Approve doses between 100 mg/m2 and 260 mg/m2 IV no more frequently than once every 21 days.

    Biliary Tract Cancer

    Approve for 1 year if ALL of the following are met

    Biliary Tract Approval: A) Patient is ≥ 18 years of age (IC-COMP) AND B) Patient meets ONE of: (i) gallbladder cancer used as neoadjuvant therapy (IC-COMP) OR (ii) unresectable, resected gross residual, or metastatic disease AND tumor type is gallbladder, intrahepatic cholangiocarcinoma, or extrahepatic cholangiocarcinoma (IC-COMP) AND C) Medication will be used in combination with gemcitabine (IC-COMP).

    Dosing: Approve ONE of: A) 125 mg/m2 IV no more frequently than twice every 21 days; OR B) 125 mg/m2 IV no more frequently than three times every 28 days.

    Kaposi Sarcoma

    Approve for 1 year if BOTH are met

    Kaposi Sarcoma Approval: A) Patient is ≥ 18 years of age (IC-COMP) AND B) Patient has tried at least one systemic chemotherapy (IC-COMP).

    Examples of systemic chemotherapy include doxorubicin and paclitaxel. Dosing: Approve 100 mg IV no more frequently than three times in each 28-day cycle.

    Small Bowel Adenocarcinoma

    Approve for 1 year if BOTH are met

    Small Bowel Approval: A) Patient is ≥ 18 years of age (IC-COMP) AND B) Patient has advanced or metastatic disease (IC-COMP).

    Dosing: Approve ONE of: A) up to 260 mg/m2 IV once every 3 weeks; OR B) up to 125 mg/m2 IV three times in each 28-day cycle.

    Kaposi Sarcoma — Initial or Subsequent Therapy

    Approve for 1 year if ALL of the following are met

    Kaposi criteria: A) Patient is ≥ 18 years of age; AND B) Patient has tried at least one systemic chemotherapy.

    Examples of systemic chemotherapy: doxorubicin, paclitaxel.

    Small Bowel Adenocarcinoma — Advanced or Metastatic Disease

    Approve for 1 year if ALL of the following are met

    Small bowel adenocarcinoma criteria: A) Patient is ≥ 18 years of age; AND B) The patient has advanced or metastatic disease.

    Dosing options per indication: up to 260 mg/m2 IV q3 weeks OR up to 125 mg/m2 IV three times per 28-day cycle.

    Vaginal Cancer — Subsequent Therapy

    Approve for 1 year if ALL of the following are met

    Vaginal cancer criteria: A) Patient is ≥ 18 years of age; AND B) The medication will be used as subsequent therapy (IC-COMP).

    Dosing: Approve up to 125 mg/m2 IV no more frequently than three times in each 28-day cycle.

    Coding lists and companion-article code tables are provided for reference to support billing and review. However, the presence or absence of a specific HCPCS or ICD-10 code alone does not determine coverage. Prior authorization decisions require clinical documentation showing the patient meets the policy’s clinical criteria and dosing requirements; codes are adjunctive and should not be used as the sole basis for approval or denial.

    Coverage is not recommended for uses that are not specified in the Recommended Authorization Criteria. Requests for indications, regimens, or clinical circumstances outside those listed in the criteria may be denied and will be reviewed only as new published data are incorporated into the policy.

    Dosing and Regimen Guidance

    RegimenIndication / NotesCoverage status
    Paclitaxel albumin‑bound in combination with carboplatin; may be used with pembrolizumab or atezolizumab as noted
    Non‑Small Cell Lung Cancer (recurrent, advanced, or metastatic); per NSCLC criteria and biomarker guidance; dosing per NSCLC node
    Per policy: covered with criteria — approval for 1 year when criteria met
    Dose / ScheduleIndicationCoverage status
    100 mg administered as an intravenous infusion no more frequently than three times in each 28‑day cycle
    Kaposi sarcoma (patient ≥18 years and has tried at least one systemic chemotherapy)
    Approve for 1 year when criteria met
    Dose OptionIndicationCoverage status
    A) Up to 260 mg/m2 IV given no more frequently than once every 3 weeks
    Small bowel adenocarcinoma (advanced or metastatic); patient ≥18 years
    Approve for 1 year when criteria met
    Dose OptionIndicationCoverage status
    B) Up to 125 mg/m2 IV no more frequently than three times in each 28‑day cycle
    Small bowel adenocarcinoma (alternative dosing listed); patient ≥18 years
    Approve for 1 year when criteria met

    Actions Required from Providers

    Prior Authorization

    Prior authorization required for Abraxane

    Prior authorization is recommended for medical benefit coverage of Abraxane; approvals are provided for the durations listed in the criteria (typically 1 year).

    Prior Authorization

    Document indication-specific criteria for approval

    Prior authorization is required and requests must document that the patient meets the indication-specific criteria (including patient age ≥ 18 years and the clinical requirements listed for the requested indication); approvals are issued for 1 year when criteria are met.

    Step Therapy

    Prior therapy required for selected indications

    Some indications require prior use of at least one other systemic therapy or systemic chemotherapy before Abraxane will be approved; examples of affected indications include unresectable or metastatic melanoma and Kaposi sarcoma.

    Coding and Age Requirements

    inv-19: Age — Patient is ≥ 18 years of age
    Age thresholdPatient is ≥ 18 years of age
    ScopeApplies to all listed oncology indications in this policy (e.g., breast, NSCLC, pancreatic, Kaposi sarcoma, etc.)
    DocumentationProviders must document patient age as part of prior authorization request
    Approval durationApprovals issued per indication are typically for 1 year

    Biomarker and Test Results

    inv-36: EGFR, ALK, RET, ROS1 (specific EGFR exon 19/21 L858R and other EGFR mutations listed)
    Required biomarker negativity for one NSCLC pathwayTumor negative for EGFR exon 19 deletion or exon 21 L858R, ALK, RET, and ROS1
    Biomarker-positive pathway supports subsequent therapyIf medication used as subsequent therapy, tumor positive for EGFR exon19/21 L858R, EGFR S768I/L861Q/G719X, RET, ALK, or ROS1 rearrangements supports use
    NotationThese biomarker requirements are denoted IC-COMP in the criteria

    Position in Treatment Course

    inv-32: first-line | subsequent — criteria node describing initial vs subsequent therapy usage positions

    Line of therapy notes: Policy supports first-line use in specific indications where guideline/compendium supports (e.g., NSCLC combination regimens; pancreatic with gemcitabine); many indications specify subsequent therapy or prior therapy requirements depending on disease (e.g., breast after prior anthracycline for metastatic disease; melanoma and Kaposi sarcoma require prior systemic therapy).

    Specific per‑indication line of therapy requirements are captured in each indication's criteria.

    inv-33: subsequent — single top-level node for subsequent therapy

    Subsequent therapy requirement: Medication will be used as subsequent therapy where indicated (e.g., cervical cancer, vaginal cancer, Kaposi sarcoma per respective criteria).

    Documentation must support prior therapies when required.

    inv-34: subsequent — single top-level node for subsequent therapy (additional reference)

    Policy Notation and Term Definitions

    inv-29: IC-COMP — Internal criteria supported by CMS‑approved compendia (notation used throughout the policy).
    DefinitionIC-COMP = internal criteria supported by CMS‑approved compendia
    UsageIC-COMP notation appears after age and clinical nodes across multiple indication criteria
    Evidence sourcesIndicates coverage criteria are supported by CMS‑approved compendia (see Sources of Information)
    inv-30: Indication notation ( ^ , @ , # ) — Symbols denote references to internal policies and relationships to NCDs/LCDs/LCAs as explained in the policy.
    Symbols and meaning^, @, # denote relationships to internal policy and NCDs/LCDs/LCAs as described in policy statement
    ^ symbolIndicates the indication is referenced in both the internal policy and applicable NCDs/LCDs/LCAs

    Background and Drug Overview

    Paclitaxel albumin‑bound (Abraxane) is a microtubule inhibitor with FDA‑labeled and guideline‑supported indications across multiple solid tumors. Indications referenced in this policy include treatment of breast cancer (including after prior anthracycline‑based therapy or in early relapse), non‑small cell lung cancer in combination with carboplatin, and metastatic pancreatic adenocarcinoma in combination with gemcitabine. Dosing schedules vary by indication and include both infrequent higher‑dose regimens (for example, up to 260 mg/m2 IV every 3 weeks) and more frequent lower‑dose schedules (for example, 100–125–150 mg/m2 IV administered up to three times per cycle).

    Policy Summary
    PayerAspirus Arise
    PolicyOncology (Injectable) - Abraxane Utilization Review Medical Policy
    Policy CodePolicy POLICY
    Change TypeNo material changes
    Effective DateJan 1, 2022
    Last ReviewOct 22, 2025
    Next Review DateOct 22, 2025
    Key ActionObtain prior authorization and document indication, age ≥18, prior therapies when required, and biomarker status as specified.
    SourceLink
    On This Page
    Recommended Authorization CriteriaDosing and Regimen GuidanceActions Required from ProvidersCoding and Age RequirementsBiomarker and Test ResultsPosition in Treatment CoursePolicy Notation and Term DefinitionsBackground and Drug Overview
    Step Therapy

    Step therapy required for Kaposi sarcoma

    For Kaposi sarcoma, prior authorization requires documentation that the patient has tried at least one systemic chemotherapy (examples provided: doxorubicin, paclitaxel) before approval.

    • Examples of systemic chemotherapy include doxorubicin and paclitaxel.
    • Approval duration when criteria met: 1 year; dosing: 100 mg IV up to three times per 28-day cycle.
    Documentation Required

    Authorization and documentation expectations

    Obtain prior authorization and include documentation of the specific indication, any required prior therapies, biomarker status when specified, patient age, and planned combination therapy as applicable to the indication.

    • Document indication and that patient is ≥ 18 years of age when applicable.
    • List prior systemic therapies when required by the indication.
    • Include biomarker results when required by the NSCLC criteria and other indication-specific requirements.
    Documentation Required

    Required clinical documentation

    Clinical documentation submitted with the prior authorization must support patient age ≥ 18 and the specific criteria for the requested indication (for example, prior systemic chemotherapy for Kaposi sarcoma or that the medication is being used as subsequent therapy where listed).

    • Examples: evidence of prior systemic chemotherapy for Kaposi sarcoma; documentation of advanced/metastatic disease for small bowel adenocarcinoma; note of subsequent‑therapy intent for vaginal cancer.
    Denial Risk

    Prior authorization and coding note — noncoverage risk

    Lack of prior authorization may lead to non-coverage; lists of HCPCS or ICD‑10 codes in companion articles are reference only and the presence or absence of a code alone does not determine approval.

    • Use companion coding lists for reference but not as sole justification for coverage.
    Denial Risk

    Coverage limitation for unlisted uses

    Coverage is not recommended for uses that are not listed in the Recommended Authorization Criteria; requests for indications outside those criteria may be denied.

    Kaposi prior chemotherapy requirement: Patient has tried at least one systemic chemotherapy prior to approval (examples include doxorubicin, paclitaxel).

    Approve for 1 year; dosing: 100 mg IV up to three times per 28-day cycle.

    inv-35: advanced/metastatic — single top-level node describing advanced/metastatic disease use

    Advanced/metastatic disease: Patient has advanced or metastatic disease (as required for small bowel adenocarcinoma and other indications where specified).

    Approve for 1 year; dosing per indication.

    @ and # symbols@ indicates internally developed criteria not referenced in NCDs/LCDs/LCAs; # indicates supported in NCDs/LCDs/LCAs but not in internal policy
    inv-31: Systemic chemotherapy — Examples provided include doxorubicin and paclitaxel.
    DefinitionSystemic chemotherapy = cytotoxic regimens given systemically (examples provided in policy)
    ExamplesDoxorubicin and paclitaxel are listed as examples of systemic chemotherapy
    Role in criteriaSome indications (e.g., Kaposi sarcoma, melanoma, ovarian recurrent disease) require prior systemic chemotherapy to be tried before approval